Who are Erivedge's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Daurismo, Daurismo, SONIDEGIB, Sonidegib Phosphate Capsules, ERIVEDGE, Treatment with vismodegib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vismodegib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Erivedge — Competitive Intelligence Brief

Erivedge (vismodegib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hedgehog Pathway Inhibitor [EPC]. Area: Oncology.

marketed Hedgehog Pathway Inhibitor [EPC] Smoothened Oncology Live · refreshed every 30 min

Target snapshot

Erivedge (vismodegib) — Roche. Vismodegib inhibits the Hedgehog pathway by binding to and blocking Smoothened, a key protein in the pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erivedge TARGET	vismodegib	Roche	marketed	Hedgehog Pathway Inhibitor [EPC]	Smoothened	2012-01-01
Daurismo	glasdegib	Pfizer	marketed	Hedgehog Pathway Inhibitor [EPC]	Smoothened homolog	2018-01-01
Daurismo	Glasdegib Maleate	Pfizer	marketed	Hedgehog pathway inhibitor	Smoothened (transmembrane protein)	2018-01-01
SONIDEGIB	SONIDEGIB		marketed		Smoothened	2015-01-01
Sonidegib Phosphate Capsules	Sonidegib Phosphate Capsules	Jemincare	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)
ERIVEDGE	ERIVEDGE	University Hospital, Lille	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)
Treatment with vismodegib	Treatment with vismodegib	University Hospital, Bordeaux	marketed	Hedgehog pathway inhibitor	Smoothened (SMO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hedgehog Pathway Inhibitor [EPC] class)

· 1 drug in this class
Pfizer · 1 drug in this class
Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erivedge — Competitive Intelligence Brief. https://druglandscape.com/ci/vismodegib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab